Amgen (NASDAQ:AMGN) Updates FY 2026 Earnings Guidance

Amgen (NASDAQ:AMGN) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 22.300-23.500 for the period, compared to the consensus earnings per share estimate of 22.390. The company issued revenue guidance of $38.2 billion-$39.4 billion, compared to the consensus revenue estimate of $37.8 billion.

Amgen Trading Up 3.1%

AMGN stock traded up $11.76 during midday trading on Tuesday, reaching $390.63. 3,450,638 shares of the company’s stock traded hands, compared to its average volume of 2,726,736. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen has a fifty-two week low of $269.77 and a fifty-two week high of $398.00. The business has a 50-day moving average price of $357.39 and a two-hundred day moving average price of $354.35. The company has a market capitalization of $210.83 billion, a P/E ratio of 27.18, a PEG ratio of 3.90 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts forecast that Amgen will post 22.31 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.6%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio is currently 70.15%.

Wall Street Analyst Weigh In

A number of brokerages have commented on AMGN. Daiwa Securities Group reduced their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. Barclays increased their price objective on shares of Amgen from $350.00 to $360.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 29th. UBS Group boosted their target price on shares of Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Argus decreased their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $357.00.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Obesity pipeline progress: Amgen extended its Phase 3 MARITIME-1-EXTENSION study, providing additional data on the durability of its experimental weight-loss treatment. The program is viewed as a potentially important long-term growth opportunity in the highly competitive obesity market. Amgen Extends Obesity Trial, Sharpening Its Long-Term Weight-Loss Bet
• Positive Sentiment: Pipeline expansion: Early-stage testing of AMG 127 signals Amgen’s efforts to enter the type 2 diabetes market, although the program remains highly speculative and is years from potential commercialization. Amgen’s AMG 127 Trial Signals a New Push Into Type 2 Diabetes
• Positive Sentiment: Earnings optimism: Pre-earnings coverage points to newer products potentially offsetting declines in Amgen’s legacy portfolio. Analysts are also assessing whether the company can exceed second-quarter expectations, supporting investor interest ahead of its report. Amgen To Report Earnings Tomorrow
• Positive Sentiment: Market backdrop: U.S. equities rallied on upbeat earnings and hopes for progress on geopolitical issues, creating a favorable environment for large-cap healthcare stocks. Equities Rally Intraday Amid Upbeat Earnings
• Neutral Sentiment: A license agreement with Kaléo gives Amgen access to patented auto-injector technology. Financial terms were not disclosed, limiting the immediate valuation impact. Kaléo Announces License Agreement with Amgen
• Neutral Sentiment: Analyst coverage currently reflects a consensus “Hold” rating, while value-stock comparisons with Bristol Myers Squibb highlight Amgen’s valuation and growth trade-offs rather than a new company-specific catalyst. Amgen Receives Consensus Hold Rating
• Negative Sentiment: Amgen disclosed a material cyber breach involving patient and proprietary information. The scope, costs, regulatory consequences and potential litigation remain uncertain, creating a risk overhang. Amgen Reveals Material Cyber Breach

Hedge Funds Weigh In On Amgen

A number of hedge funds have recently bought and sold shares of AMGN. Compound Planning Inc. lifted its stake in Amgen by 37.1% during the fourth quarter. Compound Planning Inc. now owns 9,377 shares of the medical research company’s stock worth $3,069,000 after purchasing an additional 2,537 shares during the last quarter. Claris Financial LLC bought a new stake in Amgen during the fourth quarter valued at $248,000. TMB Capital Partners LLC acquired a new stake in shares of Amgen during the fourth quarter worth $316,000. Corient Private Wealth LLC raised its holdings in shares of Amgen by 69.5% during the fourth quarter. Corient Private Wealth LLC now owns 591,748 shares of the medical research company’s stock worth $193,685,000 after purchasing an additional 242,649 shares during the period. Finally, Strive Financial Group LLC bought a new position in shares of Amgen in the 4th quarter worth about $2,409,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.